Home / Peptides / Ipamorelin
Research only — not approved

Ipamorelin

A selective growth-hormone releaser with a clean mechanism — and no finished human development

Research compound

Ipamorelin is not approved by the FDA for any use. Pharmaceutical development was discontinued, so there is no completed evidence of long-term safety or benefit in humans. Anything sold as “ipamorelin” is an unregulated research chemical. This page is educational, not medical advice.

Class

GH secretagogue

Target

Ghrelin receptor

FDA Status

Not approved

What ipamorelin is

Ipamorelin is a small synthetic peptide (a pentapeptide) that acts as a growth-hormone secretagogue: it binds the ghrelin receptor (GHSR) in the pituitary and prompts a pulse of the body's own growth hormone. It was developed by Novo Nordisk (research code NNC 26-0161). What made it notable in the research literature is its selectivity — in studies it stimulated GH release without meaningfully raising cortisol, ACTH, or prolactin, which were unwanted effects of some earlier secretagogues.

Why it’s not a medicine

A clean mechanism in early studies is not the same as a proven, approved drug. Ipamorelin was investigated for indications such as post-operative gut motility, but its clinical development was discontinued — it never completed the trials that establish efficacy and long-term safety, and it was never approved anywhere for human therapeutic use. That leaves a real evidence gap that grey-market marketing tends to paper over.

What we can and can’t say

Supported by the research

  • It reliably triggers a growth-hormone pulse via the ghrelin receptor.
  • It is relatively selective, sparing cortisol and prolactin at studied doses.
  • It came from legitimate pharmaceutical research, not a marketing lab.

Not established

  • That raising GH pulses this way produces any specific health, body-composition, or anti-aging benefit.
  • Long-term safety — development stopped before that was characterized.
  • Purity, dose accuracy, or sterility of grey-market product.
  • Any of the “stacking” claims (e.g. with CJC-1295) circulating online.

Ipamorelin is frequently paired with CJC-1295 in grey-market protocols. That combination is a marketing convention, not an approved regimen, and the safety of chronic use has not been studied.

If you're tracking a protocol, do it privately and honestly. Jabbit is an ad-free injection log — no data selling, no hype.

Download on App Store